References:
1. Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair. J Med Genet 2011;48:168-176.
2. Hebra F, Kaposi M. On diseases of the skin, including the exanthemata. New Sydenham Society 1874;61:252-258.
3. Kaposi M. Xeroderma pigmentosum. Ann Dermatol Venereol 1883; 4:29-38.
4. Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature 1968;218:652-656.
5. Piccione M, Fortina AB, Ferri G, Andolina G, Beretta L, Cividini A, et al. Xeroderma Pigmentosum: General aspects and management. J Pers Med 2021;11:1146.
6. Kleijer W, Laugel V, Berneburg M, Nardo T, Fawcett H, Gratchev A, et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair 2008;7:744-750.
7. Hirai Y, Kodama Y, Moriwaki S, Noda A, Cullings HM, MacPhee DG, et al: Heterozygous individuals bearing a non-functional allele at XPA gene exist in nearly 1% of Japanese populations. Mutat Res 2006;601:171-178.
8. Nishigori C, Nakano E, Masaki T, Ono R, Takeuchi S, Tsujimoto M, et al: Characteristics of xeroderma pigmentosum in Japan: lessons from two clinical surveys and measures for patient care. Photochemistry and Photobiology, 2019;95:140-153.
9. Moriwaki S, Kanda F, Hayashi M, Yamashita D, Sakai Y, Nishigori C, et al. Xeroderma pigmentosum clinical practice guidelines. J Dermatology 2017;44:1087-1096.
10. Sumiyoshi M, Soda H, Sadanaga N, Taniguchi H, Ikeda T, Maruta H, et al. Alert regarding cisplatin-induced severe adverse events in cancer patients with xeroderma pigmentosum. Intern Med 2017;56:979-982.
11. Nishigori C, Moriwaki S, Takebe H, Tanaka T, Imamura S. Gene alterations and clinical characteristics of xeroderma pigmentosum group A patients in Japan. Archives of Dermatology 1994;130:191-197.
12. Hauschld A, Eichstaedt J, Möbus L, Ka¨hler K, Weichenthal M, Schwarz T, et al. Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. European Journal of Cancer 2017;77:84-87.
13. Deinlein T, Lax SF, Schwarz T, Giuffrida R, Schmid-Zalaudek K, Zalaudek I. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: case report and review of the literature. Eur J Cancer 2017;83:99-102.
14. Chanbon F, Osdoit S, Bagny K, Moro Annne, Nguyen J, Reguerre Y. Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. Pediatr Blood Cancer 2018;65:e26837.
DOI: https://doi.org/10.1002/pbc.26837
15. Salomon G, Maza A, Boulinguez S, Paul C, Lamant L, Tournier E, et al. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Br J Dermatol 2018;178:1199-1203.
16. Steineck A, Krumm N, Sarthy JF, Pritchard CC, Chapman T, Stacey AW, et al. Response to pembrolizumab in a patient with xeroderma pigmentosum and advanced squamous cell carcinoma. JCO Precision Oncology 2019;3:1-6.
17. Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, et al. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Cold Spring Harb Mol Case Stud 2019;5:a004408.
DOI: https://doi.org/10.1101/mcs.a004408
18. Ameri AH, Mooradian MJ, Emerick KS, Park JC, Wirth LJ, Asgari MM, et al. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. Br J Dermatol 2019;181:1095-1097.
19. Boutros C, Rouleau E, Majer M, Nikolaev S, Robert C. Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma. European Journal of Cancer 2021;150:130-132.
20. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. THE LANCET Oncology 2020;21:1353-1365.
21. Fabrizio DA, George Jr TJ, Dunne RF, Frampton G, Sun J, Gowen K, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol 2018;9:610-617.
22. Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. Journal for ImmunoTherapy of Cancer 2019;7:183.
DOI: https://doi.org/10.1186/s40425-019-0647-4
23. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Medicine 2017;9:34.
DOI: http://doi.org/10.1186/s13073-017-0424-2
24. Li X, Peng X, Zhao S, Zhang H, Jiang Y, Liu F, et al. Combined association of tumoral PD-L1 expression and pretreatment presence of Epstein-Barr virus DNA with risk stratification and prognosis of patients with nasopharyngeal carcinoma. Front. Oncol 2022;11:791411.
DOI: https://doi.org/10.3389/fonc.2021.791411
25. Jeong JY, Park T, Ahn D. Comprehensive analysis and clinical implication of PD-L1 expression considering HPV status in oropharyngeal squamous cell carcinoma. Anticancer Research July 2020;40:4001-4010.
26. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 Expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus, and overall survival. Cancer Immunol Res 2013;1:54-63.
27. Srivastava AK, Han C, Zhao R, Cui T, Dai Y, Mao C, et al. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells. Proc Natl Acad Sci USA 2015;112:4411-4416.
28. Wu X, Fan W, Xu S, Zhou Y. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 2003;9:5874-5879.
29. Albertella MR, Green CM, Lehmann AR, O’Connor MJ. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 2005;65:9799-9806.